Use of a Belatacept-based Immunosuppression for Kidney Transplantation From Donors After Circulatory Death: A Paired Kidney Analysis.

Rita EidAnne ScemlaMagali GiralNadia ArzoukDominique BertrandMarie-Noëlle PeraldiLaurent MesnardHelene LonguetMehdi MaanaouiGeoffroy DesbuissonsEdouard LefevreRenaud Snanoudj

Published in: Transplantation direct (2024)

The use of belatacept for kidney transplants from either uncontrolled or controlled donors after circulatory death resulted in a better medium-term renal function for patients remaining on belatacept despite similar rates of delayed graft function and higher rates of cellular rejection.

Keyphrases

kidney transplantation
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
extracorporeal membrane oxygenation
prognostic factors
preterm infants
patient reported outcomes
gestational age
preterm birth